Key Highlights:
- Goldman Sachs upgrades Eli Lilly's (LLY, Financial) rating to Buy, emphasizing its strong position in the obesity drug market.
- Average analyst target price suggests a potential upside of 34.28%.
- GuruFocus estimates indicate even higher upside potential at 48.31% from current levels.
Goldman Sachs has expressed renewed confidence in Eli Lilly (LLY), upgrading its stock from Neutral to Buy. This upgrade is predominantly driven by Eli Lilly's strategic dominance in the burgeoning obesity drug market. The firm's price target for LLY has been marginally adjusted to $888. Concurrently, Goldman Sachs has updated its ratings for other biopharma companies, notably downgrading Bristol Myers, Pfizer, and AbbVie.
Wall Street Analysts' Price Forecast for Eli Lilly
As per the projections from 25 analysts, Eli Lilly and Co (LLY, Financial) holds an average one-year price target of $1,017.81. This estimate spans from a high of $1,190.00 to a low of $800.00. Based on the current trading price of $757.97, the average target price suggests a promising upside of 34.28%. For a deeper dive into these estimates, visit the Eli Lilly and Co (LLY) Forecast page.
Brokerage Firm Recommendations
Eli Lilly and Co's (LLY, Financial) current average recommendation, derived from 29 brokerage firms, stands at 1.9, which corresponds to an "Outperform" status. This rating scale ranges from 1, indicating a Strong Buy, to 5, denoting a Sell position.
GuruFocus Evaluation: GF Value
According to GuruFocus estimates, the one-year GF Value for Eli Lilly and Co (LLY, Financial) is projected at $1124.13. This represents an impressive upside potential of 48.31% from its current price of $757.97. The GF Value is an insightful measure, calculated through historical trading multiples, past business growth, and future performance projections. For further details, investors can explore the Eli Lilly and Co (LLY) Summary page.
